the impact of mrd status by clonoseq® in patients with mcl, dlbcl & fl treated with car-t therapy
Published 1 year ago • 77 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
1:49
an update on the ‘watch’ registry: clonoseq® mrd monitoring in b-cell malignancies
-
1:23
the role of mrd status & the eln 2022 in predicting clinical outcomes of patients with aml
-
3:23
the prognostic impact of pre-transplant mrd-positivity in patients with aml
-
1:38
using pet to predict failure to salvage therapy in patients with dlbcl
-
3:12
safety & efficacy of lv20.19 car-t therapy in richter's transformation and r/r mcl
-
8:46
are implanted devices mri safe?
-
1:33
wes' hlh journey (hemophagocytic lymphohistiocytosis)
-
2:41
cell avidity as a predictor of t-cell efficacy
-
1:28
novel ultra-sensitive mrd profiling tool predicts outcomes in dlbcl after frontline treatment
-
2:10
session highlights: clinical indications for car-t therapy in multiple myeloma
-
1:43
incidence & management of hlh-like toxicities after cd19 car-t therapy
-
3:19
impact of bm mrd status on the quality of organ response in al amyloidosis
-
2:59
the prognostic and therapeutic implications of mrd in aml
-
3:00
quazar aml-001: impact of mrd status on cc-486 efficacy in aml
-
3:48
mrd-driven hsct for all
-
2:13
interim analysis of phase ii study of zamto-cel in r/r dlbcl
-
2:07
the clearance of driver mutations following allosct impacts myelofibrosis disease outcomes
-
1:11
distinkt trial analysis: efficacy and safety of imc-001 for r/r enktl
-
1:59
the role of mrd as a prognostic & predictive biomarker in cll
-
1:46
phase ii study of acalabrutinib plus rice in r/r dlbcl
-
5:15
impact of mmrd and eln genetic classification in outcomes for patients with aml underoging allohct
-
2:55
lba: update on phase i study of rapcabtagene autoleucel in patients with r/r dlbcl